首页> 外国专利> Characterization of skin pigment spot apparent in human, comprises comparing expression levels, in skin samples form spot and unwounded adjacent skin, of dermal gene e.g. PLOD2 involved in the remodeling of the extracellular matrix

Characterization of skin pigment spot apparent in human, comprises comparing expression levels, in skin samples form spot and unwounded adjacent skin, of dermal gene e.g. PLOD2 involved in the remodeling of the extracellular matrix

机译:在人中明显的皮肤色素斑点的表征包括比较皮肤基因例如斑点和未受伤的邻近皮肤在皮肤样品中的表达水平。 PLOD2参与细胞外基质的重塑

摘要

Method of characterization of skin pigment spot apparent or suspected in a human, comprises comparing expression levels, in skin samples form the spot and unwounded adjacent skin, of at least a dermal gene involved in the remodeling of the extracellular matrix, comprising FRAS1, LEPREL1, MATN2, DST, PLOD2, ITGA2, COL6A3, CRTAP, LAMC1, LAMB3, LAMA3, ITGAV, ITGB1 or ACTNL. Independent claims are included for: (1) a method of evaluating the efficacy of a treatment of skin pigment spots comprising comparing expression levels, in skin samples form the spot after such a spot, before and after treatment, of the dermal gene; (2) an in vitro method for evaluating the efficacy of a treatment of skin pigment spots, comprising comparing, before and after treatment, the level of expression in a representative cellular model of the skin, of the dermal gene or the level of expression or activity of the expression product of the selected gene; (3) cosmetic method of treatment or prevention of skin pigment spot of non-pathological human skin comprising modulating the level of expression or activity of the gene, where the modulation is effected through the use of an antisense molecule, an small interfering (si)RNA, a microRNA or pulsed ultrasound of low intensity; (4) use of a modulator of the expression level or activity of the expression product of the gene, for cosmetic applications in the treatment of non-pathological skin pigment spots, where the modulator is an antisense molecule, siRNA, a microRNA, pioglitazone, miR-183, miR-29b, vitamin K2 menaquinone, beta-aminopropionitrile, low-intensity pulsed ultrasound or vandetanib (ZD6474 5); and (5) a modulator of the expression level or activity of the expression product of the dermal gene. ACTIVITY : Dermatological. MECHANISM OF ACTION : Gene expression modulator.
机译:表征人类明显或可疑的皮肤色素斑点的方法,包括比较参与斑点和未受伤的邻近皮肤的皮肤样品中至少一种涉及细胞外基质重构的真皮基因(包括FRAS1,LEPREL1, MATN2,DST,PLOD2,ITGA2,COL6A3,CRTAP,LAMC1,LAMB3,LAMA3,ITGAV,ITGB1或ACTNL。包括以下独立权利要求:(1)一种评估治疗皮肤色素斑点的功效的方法,该方法包括比较皮肤基因中该斑点之后,治疗前后的皮肤样品中该斑点的表达水平; (2)一种用于评估治疗皮肤色素斑的功效的体外方法,包括在治疗之前和之后比较代表性皮肤细胞模型中皮肤基因的表达水平,真皮基因的表达水平或所选基因表达产物的活性; (3)治疗或预防非病理性人类皮肤的皮肤色素斑的美容方法,包括调节基因的表达或活性水平,其中调节是通过使用反义分子,小的干扰(si)来实现的RNA,低强度的microRNA或脉冲超声; (4)将该基因的表达水平或表达产物的活性调节剂用于治疗非病理性皮肤色素斑的美容应用,其中该调节剂为反义分子,siRNA,microRNA,吡格列酮, miR-183,miR-29b,维生素K2甲萘醌,β-氨基丙腈,低强度脉冲超声或vandetanib(ZD6474 5); (5)真皮基因表达水平或表达产物活性的调节剂。活动:皮肤科。作用机理:基因表达调节剂。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号